Tag results:

lymphoid cells

Microenvironmental Influences on T Cell Immunity in Cancer and Inflammation

[Cellular & Molecular Immunology] Both in inflamed and cancer tissues, a wide range of changes in physical conditions and nutrient availability are now acknowledged to shape immunity.

Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8+ T Cells and Enhances Survival in Mouse Glioma Models

[Clinical Cancer Research] Researchers assessed regulatory T cells and cytotoxic T lymphocytes in the tumor microenvironment, cervical lymph nodes, spleen, and thymus; and hematopoietic stem and progenitor cells in the bone marrow.

Functional Genomics Analysis Identifies T and NK Cell Activation as a Driver of Epigenetic Clock Progression

[Genome Biology] Four clocks resulted in similar predictions of individual chronological age, and their constituting CpGs were correlated in DNA methylation level and were enriched for similar histone modifications and chromatin states.

Endothelial Thrombomodulin Downregulation Caused by Hypoxia Contributes to Severe Infiltration and Coagulopathy in COVID-19 Patient Lungs

[Ebiomedicine] Pulmonary endothelial cells become dysfunctional during COVID-19, showing a loss of thrombomodulin expression related to severe thrombosis and infiltration, and endothelial cell dysfunction might be caused by a pathologic condition in COVID-19 patient lungs rather than a direct infection with SARS-CoV-2.

Synergistic Activity of Combined Inhibition of Anti-apoptotic Molecules in B-cell Precursor ALL

[Leukemia] When analyzing the effects of BH3-mimetics selectively targeting BCL-XL and MCL-1 alone or in combination with the BCL-2 inhibitor venetoclax, heterogeneous sensitivity to either of these inhibitors was found in ALL cell lines and in patient-derived xenografts.

Overcoming Resistance to Immune Checkpoint Therapy in PTEN-Null Prostate Cancer by Intermittent Anti-PI3Kα/β/δ Treatment

[Nature Communications] Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.

Popular